Safety and immunogenicity of H5N1 vaccine

被引：3

作者：

Authier, F. J. ^{[1
]}

Gherardi, R. K. ^{[1
]}

机构：

[1] Univ Paris 12, Fac Med, Henri Mondor Hosp,AP HP, INSERM,E0011,Reference Ctr Neuromuscular Disorder, F-94000 Creteil, France

来源：

LANCET | 2006年 / 368卷 / 9554期

关键词：

D O I：

10.1016/S0140-6736(06)69891-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2209 / 2210

页数：2

共 50 条

[21] Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
Chen, Wilbur H.
Jackson, Lisa A.
Edwards, Kathryn M.
Keite, Wendy A.
Hill, Heather
Noah, Diana L.
Creech, C. Buddy
Pate, Shital M.
Manga, Brian
Kotloff, Karen L.
OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (03):
[22] The Length of N-Glycans of Recombinant H5N1 Hemagglutinin Influences the Oligomerization and Immunogenicity of Vaccine Antigen
Maciola, Agnieszka Katarzyna
Pietrzak, Maria Anna
Kosson, Piotr
Czarnocki-Cieciura, Mariusz
Smietanka, Krzysztof
Minta, Zenon
Kopera, Edyta
FRONTIERS IN IMMUNOLOGY, 2017, 8
[23] Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)
Oshansky, Christine M.
Zhou, James
Gao, Yonghong
Schweinle, Jo Ellen
Biscardi, Karen
DeBeauchamp, Jennifer
Pavetto, Corrina
Wollish, Amy
Webby, Richard J.
Cioce, Vittoria
Donis, Ruben O.
Bright, Rick A.
Armstrong, Kimberly
Gibson, Laura
Hylton, Penny
Jackson, Angela
King, James
Little, James
O'Hara, Michael
Robinson-Wright, Katina
Tresnjak-Smith, Silvija
Walker, Robert
Yeh, Bai
Yeskey, Debra
VACCINE, 2019, 37 (03) : 435 - 443
[24] Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial
Keitel, Wendy
Groth, Nicola
Lattanzi, Maria
Praus, Michaela
Hilbert, Anne Katrin
Borkowski, Astrid
Tsai, Ted F.
VACCINE, 2010, 28 (03) : 840 - 848
[25] Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults
Yang, Pan-Chyr
Yu, Chong-Jen
Chang, Shan-Chwen
Hsieh, Szu-Min
Drame, Mamadou
Walravens, Karl
Roman, Francois
Gillard, Paul
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2012, 111 (06) : 333 - 339
[26] Safety and immunogenicity of an influenza vaccine A/H5N1 administered with and without a heat-labile enterotoxin (LT) patch in healthy adults
Glenn, G. M.
Frech, S. A.
Wen, J.
Thomas, D. N.
VACCINE, 2008,
[27] Development of broadly reactive H5N1 vaccine against different Egyptian H5N1 viruses
Ibrahim, Mahmoud
Sultan, Hesham A.
Razik, Alaa G. Abdel
Kang, Kyung-il
Arafa, Abdel Satar
Shehata, Awad A.
Saif, Yehia M.
Lee, Chang-Won
VACCINE, 2015, 33 (23) : 2670 - 2677
[28] Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
Lin, Jiangtao
Zhang, Jiansan
Dong, Xiaoping
Fang, Hanhua
Chen, Jiangting
Su, Nan
Gao, Qiang
Zhang, Zhenshan
Liu, Yuxuan
Wang, Zhihong
Yang, Meng
Sun, Ruihua
Li, Changgui
Lin, Su
Ji, Mei
Liu, Yan
Wang, Xu
Wood, John
Feng, Zijian
Wang, Yu
Yin, Weidong
LANCET, 2006, 368 (9540): : 991 - 997
[29] Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population
van der Velden, Maikel V. W.
Fritz, Richard
Poellabauer, Eva Maria
Portsmouth, Daniel
Howard, M. Keith
Kreil, Thomas R.
Dvorak, Thomas
Fritsch, Sandor
Vesikari, Timo
Diez-Domingo, Javier
Richmond, Peter
Lee, Bee Wah
Kistner, Otfried
Ehrlich, Hartmut J.
Barrett, P. Noel
Aichinger, Gerald
JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (01): : 12 - 23
[30] An inactivated subvirion influenza A (H5N1) vaccine
Focosi, D
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (25): : 2724 - 2725

← 1 2 3 4 5 →